Yahoo · Sep 25, 2026
UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base
UroGen Pharma has seen its share price move sharply over recent years, which naturally puts a spotlight on whether the current valuation lines up with the sales the business is generating. For anyone looking at the stock today, the core issue is how much of that move can be explained by the company’s revenue base rather than by sentiment alone. Over the past 3 years the stock has delivered a gain of 188.5%, which raises the question of how closely that share price climb tracks the growth in...
